In Silico/Computer-Aided Drug Discovery Services Market, 2020-2030 - Key Step(s) of Drug Discovery, Types of Large Molecules, Company Sizes, Therapeutic Areas, Types of Clientele, Key Regions
DUBLIN, April 23, 2020 /PRNewswire/ -- The "In Silico/Computer-Aided Drug Discovery Services Market: Focus on Large Molecules" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Over 30% of the total cost invested in developing a new drug can be saved by utilizing in silico services. However, this is highly variable and is dependent upon the nature of drug discovery projects.
This report features an extensive study on the current landscape and the likely future potential of the companies offering services for the discovery of large molecule drugs based on the use of in silico tools and techniques. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders.
One of the key objectives of this report was to understand the primary growth drivers and estimate the future size of the in silico drug discovery services market. Based on several parameters, such as number of large molecules based drug discovery projects, adoption of in silico services for drug discovery and outsourcing profile, we have provided informed estimates on the likely evolution of the market for the period 2020-2030.
The report also provides details on the likely distribution of the current and forecasted opportunity across:
-- [A] key step(s) of drug discovery (target identification, target
validation, hit generation, hit-to-lead and lead optimization)
-- [B] type of large molecule (antibodies, proteins, peptides, nucleic
acids and vectors)
-- [C] company size (small, mid-sized and large)
-- [D] therapeutic area (autoimmune disorders, blood disorders,
cardiovascular disorders, gastrointestinal and digestive disorders,
hormonal disorders, HIV / AIDS, infectious diseases, metabolic
disorders, mental disorders, musculoskeletal disorders, neurological
disorders, oncological disorders, respiratory disorders, skin disorders,
urogenital disorders and others)
-- [E] type of clientele (pharmaceutical / biotechnology companies and
academic / research institutes)
-- [F] key geographical regions (North America (the US and Canada), Europe
(Italy, Germany, France, Spain and rest of Europe) and Asia-Pacific
(China, India and Japan), along with the rest of the world)
The process of drug development, beginning from the discovery of a pharmacological lead to its commercial launch, is estimated to take around 10-15 years, involving capital investments in the range of USD 4-10 billion. Moreover, it is well-known that only a small proportion of leads, which are selected for further investigation during the initial stages of research, are actually translated into product candidates for clinical research studies. Over time, the complexities of drug discovery, have increased; this is especially true for large molecules, which are inherently more complex than conventional small molecule drugs. As a result, there has been a direct rise in overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector.
Specifically, in 2019, the global R&D spending was estimated to be around USD 182 billion, with over 16,000 drug molecules reported to have been investigated. Presently, the industry is currently under tremendous pressure to identify ways to cope with rising capital requirements in drug discovery research and actively avoid losses owing to failed drug development programs. In addition, there has been an evident increase in regulatory stringency, which has made the drug approval process, especially for large molecules, significantly more difficult.
During the last several years, several computational tools have been developed and introduced for enabling the identification, selection and optimization of pharmacological lead candidates. Currently, there are several in silico approaches available for the drug discovery process alone, such as structure based drug design, fragment based drug discovery and ligand based drug discovery. The predictive power of these in silico tools has been proven to be very advantageous, allowing researchers to bypass the random screening of billions of molecules across hundreds of large molecule targets.
According to industry experts, almost 35% of the total cost and time invested in developing a new drug can be saved by adopting an in silico approach. As a result, companies offering in silico drug discovery services, such as computer-aided drug design (CADD), molecular modeling and quantitative structure-activity relationship (QSAR), have now become an important part of the pharmaceutical industry. In future, drug developers, especially those focused on the development of large molecules, are likely to continue relying on outsourcing for a significant part of their respective drug discovery and development operations.
In addition to other elements, the report includes:
-- A detailed review of the overall landscape of companies offering in
silico drug discovery services for large molecules, including
information on year of establishment, company size, location of
headquarters, type of business model used (contract service providers
(CROs), software / technology providers, consulting service providers
and training service providers), number of drug discovery step(s) for
which the company offers services involving the use of in silico
approaches (target identification, target validation, hit generation,
hit-to-lead and lead optimization), type of large molecules(s) handled
(antibodies (monoclonal antibodies, bispecific antibodies, polyclonal
antibodies, antibody drug conjugates (ADCs), antibody fragments, single
domain antibodies, antisense antibodies and others), proteins (fusion
proteins, protein fragments, enzymes and hormones), peptides, cell
therapies, gene therapies, vectors and nucleic acids), type of in silico
approach used (structure-based drug design (SBDD), fragment-based drug
design (FBDD), target-based drug design (TBDD), ligand-based drug design
(LBDD) and interface-based drug design (IBDD)), type of in silico
service(s) offered (virtual screening, molecular docking, molecular
modeling, scaffold hopping and 8+ services), and type of clientele
served (pharmaceutical / biotechnology companies and academic / research
institutes).
-- Insights on contemporary market trends, depicted using four schematic
representations, which include [A] a logo landscape of the industry
players engaged in this domain, distributed based on the basis of
location of their company size (small (1-50 employees), mid-sized
(51-200 employees) and large (>200 employees)) and respective
headquarters, [B] a tree map representation of in silico service
providers, featuring a distribution of stakeholders on the basis of the
company size and drug discovery steps, [C] a world map representation,
highlighting the key hubs with respect to outsourcing activity within
this domain, and [D] an insightful grid analysis, presenting the
distribution of companies based on the type of large molecule, in silico
approach used and type of clientele.
-- Elaborate profiles of key industry players that offer a wide range of in
silico drug discovery services, featuring a brief overview of the
company (including details related to year of establishment, company
size, location of headquarters and key members of the executive team),
funding and investment information (if available), in silico-based
service(s) portfolio) and an informed future outlook.
-- A detailed peer group-based benchmarking analysis, comparing the
involved players based on several relevant parameters, such as the
experience of the company, number of drug discovery step(s), number of
in silico service(s) offered, number of large molecule(s) for which the
aforementioned services are offered and type of clientele.
-- An insightful competitiveness analysis featuring a four-dimensional
bubble chart, highlighting the key players in this domain on the basis
of the strength of their respective service portfolios, taking into
consideration the experience of a service provider, number of drug
discovery services offered and number of large molecules, for which the
aforementioned services are offered.
-- A detailed analysis assessing the current opportunity within in silico
drug discovery services market, comparing the number of pipeline
products and current market size across different types of large
molecules, and the availability and capabilities of affiliated in silico
drug discovery service providers.
-- A discussion on the various business strategies that can be adopted by
in silico drug discovery service providers in order to maintain a
competitive edge in this industry, based on the different types of large
molecules handled and the technical expertise of service providers, in
terms of capabilities across different steps of drug discovery.
-- An insightful analysis highlighting the cost saving potential associated
with the use of in silico approaches in the drug discovery process.
-- A case study comparing the key challenges associated with the discovery
and production of large molecules, affiliated product development
timelines, and manufacturing protocols, with those of small molecule
drugs.
-- Insights from an industry-wide survey, featuring inputs solicited from
various experts who are directly / indirectly involved in providing in
silico services for discovery of large molecule drugs.
-- A discussion on the upcoming computational approaches (such as
artificial intelligence and cloud computing) that are being adopted for
drug discovery purposes and are likely to impact early stage research
over the coming years.
-- A case study highlighting several non-computational methods /
technologies, which are considered to be of significant importance to
the overall drug discovery process.
In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
The opinions and insights presented in this report were also influenced by inputs solicited via a survey and discussions held with senior stakeholders in the industry.
The report features detailed transcripts of discussions held with the following individuals (in alphabetical order):
-- John L Kulp (Chief Executive Officer and Chief Technical Officer,
Conifer Point)
-- Sven Benson (Founder, candidum)
-- Mark Whittaker (Senior Vice President, Evotec)
-- Edelmiro Moman (Scientific Consultant and Teacher, ProSciens)
Companies Mentioned
-- 16S Technologies
-- Ab Studio
-- AbbVie
-- AbCheck
-- Abzena
-- Adagio Pharmaceuticals
-- Adimab
-- Advent International
-- Ajinomoto Bio-Pharma
-- Allesh Biosciences Labs
-- Allosterix Pharmaceuticals
-- Ambrx
-- AMRI
-- Antitope (acquired by Abzena)
-- Antiverse
-- ApconiX
-- Aprecia Pharmaceuticals
-- Aptuit
-- AsiaVest Partners
-- AstraZeneca
-- ATHOS Service
-- Avistron Chemistry Services
-- Bayer Animal Health
-- BDG LifeSciences
-- BenevolentAI
-- Berkeley Lights
-- Betta Biomedical Industry Fund
-- BIANA
-- Bill & Melinda Gates Foundation
-- BioAscent
-- BioBench Solutions
-- Bioclinica
-- BioDuro
-- BioGlobal Consulting Group
-- BioNTech
-- Biotech Investment Group
-- BIOTEM
-- BMG LABTECH
-- Broad Institute of MIT and Harvard
-- BVCF Management
-- Caldan Therapeutics
-- CALIXAR
-- candidum
-- CardioVascular Research Foundation
-- CARLBio
-- Catalent Pharma Solutions
-- CELLSCRIPT
-- Charles River Laboratories
-- ChemBio Discovery Solutions
-- ChemBridge
-- ChemDiv
-- ChemoGenics BioPharma
-- ChemPartner
-- Cloud Pharmaceuticals
-- CompChem Solutions
-- Concept Life Sciences
-- Conifer Point
-- Conifer Point Pharmaceuticals
-- Creative Biolabs
-- Creative Biostructure
-- Creative Diagnostics
-- Cyclica
-- Cyprotex
-- Defense Advanced Research Projects Agency
-- Domainex
-- DuPont
-- Eli Lilly
-- European Investment Bank
-- Evotec
-- Fidelity Management & Research
-- Fidelta (a CRO Subsidiary of Galapagos)
-- Formex
-- Fractal Therapeutics
-- Fusion Antibodies
-- Genedata Biologics
-- Genentech
-- Genevant Sciences
-- Genmab
-- Genomodel
-- GenScript
-- Gfree Bio
-- Greenpharma
-- Harlan Laboratories
-- Harvard University
-- HiFiBiO
-- HQL Pharmaceuticals
-- IBM Watson
-- Icagen
-- ICON
-- IDG Capital
-- ImmunoPrecise Antibodies
-- In-Cell-Art
-- Insilico Medicine
-- Inte:Ligand
-- Integral Molecular
-- Invus
-- IRBM
-- Ironwood Pharmaceuticals
-- IXTAL
-- Janssen
-- Janus Henderson Investors
-- Jebsen Capital
-- JPT Peptide Technologies
-- Jubilant Biosys
-- Keapstone Therapeutics
-- LakePharma
-- Lead Discovery Center
-- LeadInvent Technologies
-- Life Technologies
-- MabVax Therapeutics
-- Mascot Industries
-- Merck
-- Metropolis Healthcare
-- Micar Innovation
-- MIG Funds
-- Mind the Byte
-- Mirae Asset
-- Molecular Devices
-- Molecular Forecaster
-- Molecular Response
-- Moleculomics
-- Molsoft
-- N2 Business Growth Fund
-- NIH
-- NovaData Solutions
-- NovAliX
-- Novartis
-- Novo Informatics
-- NuChem Therapeutics
-- Numerate
-- NYU Langone Health
-- Oscotec
-- PacificGMP
-- Patheon
-- Pathios Therapeutics
-- Peak Proteins
-- Pelago Bioscience
-- Pepscan
-- Peptone
-- Pfizer
-- Pharma Inventor
-- Pharmacelera
-- Pharmacia
-- Phoenix Equity Partners
-- Platinum Asset Management
-- PolyTherics (acquired by Abzena)
-- Porton Pharma Solutions
-- PPD
-- Prestwick Chemical (acquired by Bionomics)
-- Profacgen
-- ProMab Biotechnologies
-- Prosarix
-- ProteinQure
-- ProteoGenix
-- Provid Pharmaceuticals
-- PX'Therapeutics
-- QIAGEN
-- Quantitative Medicine
-- RASA Life Science Informatics
-- Redmile Group
-- RedX Pharma
-- Roche
-- Rosa
-- Rosetta Design Group
-- RuiYi
-- Sai Life Sciences
-- Sandexis
-- Sandoz
-- Sanofi
-- Schering Plough
-- Schrdinger
-- Shuwen Biotech
-- SilcsBio
-- Sitryx
-- Sonnet BioTherapeutics
-- Sosei Heptares
-- Steam Athena Capital
-- Struengmann Family Office
-- Sundia MediTech
-- Sygnature Discovery
-- Syngene
-- Taros Chemicals
-- Telix Pharmaceuticals
-- The Chemistry Research Solution (acquired by Abzena)
-- Tmunity Therapeutics
-- TRIANNI
-- University of Pennsylvania
-- UPM
-- Viramatix
-- Virtua Drug
-- Viva Biotech
-- Viva Vision
-- Warwick Effect Polymers
-- WuXi AppTec
-- Wyss Institute
-- YUMAB
-- ZoBio
-- Zorilla Research
For more information about this report visit https://www.researchandmarkets.com/r/sui33j
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
